Connetics plans new trial for Extina

Seven months after receiving a not approvable letter from the FDA for Extina -- an experimental skin treatment -- Connetics says it will begin a late-stage trial in the third quarter to prove it works. Extina was developed for an inflammatory skin disease called seborrhic dermatitis. Connetics says its new schedule will put it on track to file another NDA on the treatment in the second half of 2006.

- read this story from Forbes for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.